High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome

Transplantation Proceedings

Volumn 40, Issue 10, 2008, Pages 3375-3380

  Iv, R ^a   He, Q ^a   Wang, H P ^a   Jin, J ^a   Chen, Y ^a   Chen, J H ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD30 ANTIGEN; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PANEL REACTIVE ANTIBODY; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DIALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD30; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHINA; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 57549107137     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.173     Document Type: Article

References (23)

1. Hawkins B.R., Chan P., Chan Y.T., et al. Highly successful long-term outcome of kidney transplantation in Chinese recipient: an enhancing race effect?. Clin Transplant 11 (1997) 178
2. Wu J.Y., Chen J.H., Wang Y.M., et al. Improved clinical outcomes in Chinese renal allograft recipients receiving lower dose immunosuppressants. Transplantation 78 (2004) 713
3. Schwab U., Stein H., Gerdes J., et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299 (1982) 65
4. Falini B., Pileri S., Pizzolo G., et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85 (1995) 1
5. Susal C., Pelzl S., Dohler B., et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13 (2002) 1650
6. Pelzl S., Opelz G., Daniel V., et al. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75 (2003) 421
7. Rajakariar R., Jivanji N., Varagunam M., et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 5 (2005) 1922
8. Cinti P., Pretagostini R., Arpino A., et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 80 (2005) 1638
9. Dai Z., Li Q., Wang Y., et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest J 113 (2004) 310
10. Hargreaves P.G., and Al-Shamkhani A. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol 32 (2002) 163
11. Shimmura H., Tanabe K., Tokumoto T., et al. Analysis of cause of death with a functioning graft: a single-center experience. Transplant Proc 36 (2004) 2026
12. Price P., Murray R.J., John M.F., et al. High circulating levels of soluble CD30 correlate with impaired delayed-type hypersensitivity responses in HIV-infected patients. AIDS 13 (1999) 2308
13. Kerman R.H., Orosz C.G., and Lorber M.I. Clinical relevance of anti-HLA antibodies pre and post transplant. Am J Med Sci 313 (1997) 275
14. Fernandez-Fresnedo G., Pastor J.M., Lopez-Hoyos M., et al. Clinical relevance of posttransplantation HLA antibody monitoring by ELISA. Transplant Proc 35 (2003) 701
15. Nordoy I., Muller F., Nordal K.P., et al. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 181 (2000) 51
16. Stone S.F., Price P., Tay-Kearney M.L., et al. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 185 (2002) 1813
17. Couchoud C., Cucherat M., Haugh M., et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 65 (1998) 641
18. Schurman S.J., and McEnery P.T. Factors influencing short-term and long-term pediatric renal transplant survival. J Pediatr 130 (1997) 455
19. Mange K.C., Joffe M.M., and Feldman H.I. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 344 (2001) 726
20. Kaul H., Girndt M., Sester U., et al. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis 35 (2000) 611
21. Sakata-Kaneko S., Wakatsuki Y., Matsunaga Y., et al. Altered Th1/Th2 commitment in human CD4+ T cells with ageing. Clin Exp Immunol 120 (2000) 267
22. Krampera M., Vinante F., Tavecchia L., et al. Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol 117 (1999) 291
23. Nakao K., Nagake Y., Okamoto A., et al. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nephron 91 (2002) 215